Express Scripts (ESRX) shares advancing through a positive trading channel


An active pharmacy benefits manager should smooth the path between patients and their prescription medications. There is an outfit in St Louis that handles the job well. It was the recipient of Fortune's first-ever "Streetie Award" for the best overall performance by any company.

Express Scripts (NASDAQ: ESRX) is one of the largest pharmacy benefit management companies in North America, serving over 50 million members through managed-care organizations, insurance carriers, employers and workers compensation groups. Services include network-pharmacy claims processing, formulary management, home delivery services, drug-utilization review, disease management and medical-data analysis services. The company also distributes a full range of injectable and infusion biopharmaceutical products directly to patients.

The stock has been a steady gainer recently, rising on such developments as solid Q3 earnings, upside guidance for FY07/FY08 EPS and favorable analyst remarks. The news has kept ESRX shares cycling through a positive eight-week trading channel. The price is currently consolidating at the base of that channel, where oversold Momentum, MACD and Stochastic technical parameters suggest the potential for a rise back toward the top. The correspondence of the stock's 30-day moving average to the base of the channel backs the rebound notion.

Brokers recommend the issue with eight "strong buys", eight "buys" and five "holds". Analysts expect a 23% growth rate, through the next year. The ESRX Price to Sales ratio (0.96), EPS Growth rate (46.34%), Return on Assets (11.52%), Return on Investment (21.79%), Return on Equity (76.45%) and Revenue per Employee ($1.61M) compare favorably with industry, sector and S&P 500 averages. Institutions hold about 88% of the outstanding shares. The stock is one of those used to calculate the S&P 500 Index. Over the past 52 weeks, it has traded between $32.32 and $73.55. A stop-loss of $60.70 looks good here. Note that the firm is expected to report Q4 results in early February.

Larry Schutts is a contributing editor for Theflyonthewall.com and the Vice-President of Stockwinners.com.

Symbol Lookup
IndexesChangePrice
DJIA-89.2312,801.23
NASDAQ-23.352,903.88
S&P 500-9.311,342.64

Last updated: February 13, 2012: 06:21 AM

Hot Stocks

General Electric

18.875-0.255(-1.33)

Alcoa

10.29-0.35(-3.29)

Apple Inc

493.42+0.25(+0.05)

Google Inc 'A'

605.91-5.55(-0.91)

Bank of America

8.07-0.11(-1.34)

Wal-Mart Stores

61.90-0.06(-0.10)

Exxon Mobil Corp

83.80-1.08(-1.27)

Ford

12.44-0.25(-1.97)

Citigroup

32.925-0.735(-2.18)

IBM

192.42-0.71(-0.37)

Yahoo

16.14+0.14(+0.88)

Starbucks

48.82-0.38(-0.77)

Microsoft

30.495-0.275(-0.89)

Home Depot

45.33+0.06(+0.13)

DailyFinance Headlines

Benzinga Headlines

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

DailyFinance BlackBerry App

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

BioHealth Investor Headlines

Page Loaded in 1329132066419 ms.